Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666562 · ClinicalTrials.gov registry record · Phase 2
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00666562: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00666562 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666562, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Green tea extract contains ingredients that may slow the growth of certain cancers. It is not yet known whether green tea extract is more effective than a placebo when given before surgery in treating patients with bladder. This randomized phase II trial is studying green tea extract to see how well it works compared to a placebo when given before surgery in treating patients with nonmetastatic bladder cancer.
Interventions
- DRUG Placebo
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- OTHER Pharmacological Study
- DIETARY_SUPPLEMENT Defined Green Tea Catechin Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-07-02 |
| Est. Completion | 2017-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666562
The ClinicalTrials.gov registry entry for NCT00666562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00666562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666562 about?
NCT00666562 is a clinical study titled "Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer". Green tea extract contains ingredients that may slow the growth of certain cancers. It is not yet known whether green tea extract is more effective than a placebo when given before surgery in treating patients with bladder. This randomized phase II trial is studying green tea extract to see how well...
What is the current status of trial NCT00666562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2008-07-02. Estimated completion is 2017-06-09.
What interventions are being tested in trial NCT00666562?
The interventions under investigation include: Placebo (DRUG), Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Pharmacological Study (OTHER), Defined Green Tea Catechin Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00666562?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.